Tadalafil Tablet, Film Coated
Product Images NDC 69097-526

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 69097-526). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 01

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 02

F5c8b23e 51e5 4264 8328 437c9d11939a 02
This is a table showing the effects of coadministered drugs with Tadalafil 20mg on blood pressure. The table includes Max Decrease in Standing/Sitting Blood Pressure over Placebo and Mean Differences.*
FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 03

F5c8b23e 51e5 4264 8328 437c9d11939a 03
This is a chart listing co-administered drugs, including CYP3A inhibitors, inducers, antacids, and H2 antagonists, and their effects on AUC and Cmax levels in relation to Tadalafil. The chart recommends either dose adjustment or avoiding use altogether for certain drugs. There is also a fold change column indicating the change relative to Tadalafil alone.*
FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 04

F5c8b23e 51e5 4264 8328 437c9d11939a 04
This is a table showing the effects of coadministered drugs on various substrates in the body. The substrates include CYP1A2, CYP2C9, CYP3A, P-glycoprotein, oral contraceptives, and NSAIDs. The effects are measured in terms of AUC and Cmax, and the fold change and 90%Cl recommendations are given. The table suggests that for most of the substrates, no dose adjustment is necessary when the drugs are coadministered.*
FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 05

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 06

FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 07

F5c8b23e 51e5 4264 8328 437c9d11939a 07
The text is a chart depicting the percentage of subjects without clinical worsening for Tadalafil 40 mg, Tadalafil 20 mg, and Placebo. It also shows the time to clinical worsening in days.*
FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 08

F5c8b23e 51e5 4264 8328 437c9d11939a 08
This is a description for a prescription drug called Tadalafil. It is manufactured by Cipla and comes in a pack of 60 tablets. The text provides the NDC code 69097-526-03, and states that it is for prescription use only. There is also information on its expiration date, lot number, and a space for printing batch information.*
FDA Label Image

F5c8b23e 51e5 4264 8328 437c9d11939a 09

F5c8b23e 51e5 4264 8328 437c9d11939a 09
This is a description of Tadalafil Tablet, USP manufactured by Goa Ltd in India for Cipla USA, Inc. The tablet is available in 20mg dosage. The NDC number of the product is 63097-526-16. The text provides instructions on how to remove the tablet from the blister pack. The remaining text appears to be a mix of numbers, codes, and characters that are not easily understandable.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.